Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and has been approved for the treatment of rheumatoid arthritis (RA) patients who have had an inadequate response to previous biological therapies. Psoriasiform skin lesions, especially palmoplantar pustulosis lesions, are well described following anti-tumour necrosis factor therapy. We describe a 79-year-old woman with rheumatoid factor-positive, anti-citrullinated protein antibody-positive erosive RA, who developed a psoriasiform palmoplantar pustulosis reaction following treatment with TCZ therapy (IL-6 receptor). The rash showed histological features compatible with psoriasis and disappeared following discontinuation of TCZ.

2.
Nakamura M, Tokura Y: Tocilizumab-induced erythroderma. Eur J Dermatol 2009;19:273-274.
3.
Yoshiki R, Nakamura M, Tokura Y: Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol 2009;24:495-496.
4.
Izquierdo JH, et al: Acute generalized exanthematous pustulosis due to tocilizumab in a rheumatoid arthritis patient. Case Rep Rheumatol 2012;2012:517424.
5.
Wendling D, et al: Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol 2012;39:657.
6.
Brulhart L, et al: Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010;77:625-626.
7.
Younis S, et al: Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker. J Rheumatol 2012;39:2055-2056.
8.
Rueda-Gotor J, et al: Successful effect of tocilizumab in anti-TNF-alpha-induced palmoplantar pustulosis in rheumatoid arthritis. Joint Bone Spine 2012;79:510-513.
9.
Joyau C, et al: Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30:700-706.
10.
Harrison MJ, et al: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-215.
11.
Puig L, et al: Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012;225:14-17.
12.
Ogata A, Kumanogoh A, Tanaka T: Pathological role of interleukin-6 in psoriatic arthritis. Arthritis 2012;2012:713618.
13.
Laurent S, et al: Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010;163:1364-1365.
14.
Neuner P, et al: Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 1991;97:27-33.
15.
Grossman RM, et al: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367-6371.
16.
Miyoshi K, et al: Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011;131:108-117.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.